Insiders Make Huge Buys in Gold Miners and More
In the past week or so, a couple of gold-mining stocks attracted the attention of insider buyers.
Repricing Potential Driven By Deleveraging
Bausch Health is significantly undervalued, trading at depressed multiples due to high debt and patent risk, but its core business remains stable and cash generative. Recent refinancing has extended debt maturities past 2027, giving management time to monetize assets and reduce leverage before Xifaxan's patent expires in 2028. Despite risks—$21.5B debt, Xifaxan patent cliff, and regulatory uncertainty—the company's strong revenue, EBITDA, and asset base support a 12-18 month target of $8-10 per share.
Why Is Bausch (BHC) Down 13% Since Last Earnings Report?
Bausch (BHC) reported earnings 30 days ago. What's next for the stock?
Bausch Health Q1 Earnings and Revenues Miss Estimates, Stock Down
BHCs first-quarter 2025 adjusted earnings and revenues miss estimates. Salix performs lower than expected.
Bausch (BHC) Reports Q1 Earnings: What Key Metrics Have to Say
The headline numbers for Bausch (BHC) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Bausch Health (BHC) Q1 Earnings and Revenues Lag Estimates
Bausch Health (BHC) came out with quarterly earnings of $0.59 per share, missing the Zacks Consensus Estimate of $0.83 per share. This compares to earnings of $0.59 per share a year ago.
Bausch Health Companies Inc. (BHC) Q1 2025 Earnings Call Transcript
Bausch Health Companies Inc. (NYSE:BHC ) Q1 2025 Earnings Conference Call April 30, 2025 5:00 PM ET Company Participants Garen Sarafian - IR Thomas Appio - CEO Jean-Jacques Charhon - EVP & CFO Conference Call Participants Les Sulewski - Truist Securities Doug Miehm - RBC Capital Michael Nedelcovych - TD Cowen Jason Gerberry - Bank of America Michael Freeman - Raymond James Operator Greetings. Welcome to the Bausch Health First Quarter 2025 Earnings Call.
Will Bausch (BHC) Beat Estimates Again in Its Next Earnings Report?
Bausch (BHC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Bausch Health (BHC) Reports Next Week: Wall Street Expects Earnings Growth
Bausch (BHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bausch (BHC) Moves 13.3% Higher: Will This Strength Last?
Bausch (BHC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Bausch Health: Repositioning Aplezin As First Oral Monotherapy For TRD A $3 Billion Opportunity
One-eighth of the global population and one-fifth of U.S. adults suffer from mental health conditions, highlighting an urgent need for better psychiatric care. Bausch Health's Aplenzin shows promise for treatment-resistant depression (TRD), potentially offering better efficacy and tolerability compared to Wellbutrin, addressing a significant unmet medical need. Repositioning Aplenzin for TRD could unlock a $3 billion market opportunity, aiding Bausch Health's financial recovery and providing substantial clinical benefits.
Bausch + Lomb recalls some of its implantable eye lenses
Bausch + Lomb said on Thursday it will recall some of its implantable eye lenses after receiving reports of complications, the cause of which could not immediately be known.
